Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 3/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | CASP3 | P42574 | 1/20 | 0.39 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.39 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.39 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.34 |
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.34 |
| ▸ | DPP4 | P27487 | 1/20 | 0.33 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.33 |
| ▸ | AAK1 | Q2M2I8 | 3/20 | 0.33 |
| ▸ | JAK2 | O60674 | 1/20 | 0.33 |
| ▸ | JAK1 | P23458 | 1/20 | 0.33 |
| ▸ | TYK2 | P29597 | 1/20 | 0.33 |
| ▸ | JAK3 | P52333 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18901586 | 1.00 | USP30 (0.50) | USP30NPC1RAB9ACASP3SENP8 | |
| SCHEMBL883168 | 0.84 | KMT2A (0.41) | NPC1RAB9AALDH1A1 | |
| SCHEMBL18901982 | 0.84 | KMT2A (0.41) | NPC1RAB9AALDH1A1 | |
| SCHEMBL10182560 | 0.84 | USP30 (0.47) | USP30NPC1RAB9ACASP3SENP8 | |
| SCHEMBL10183425 | 0.83 | USP30 (0.48) | USP30NPC1RAB9ACASP3SENP8 | |
| SCHEMBL1293820 | 0.83 | ALDH1A1 (0.36) | USP30NPC1RAB9AALDH1A1 | |
| SCHEMBL13258502 | 0.82 | USP30 (0.46) | USP30NPC1RAB9ACASP3SENP8 | |
| SCHEMBL12333081 | 0.81 | KMT2A (0.40) | NPC1RAB9AGPR119 | |
| SCHEMBL18467520 | 0.78 | NPC1 (0.36) | USP30NPC1RAB9AALDH1A1GPR119 | |
| SCHEMBL13827079 | 0.78 | NPC1 (0.36) | USP30NPC1RAB9AALDH1A1GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2912031-B1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-05-31 | — | — | EP | disclosed |
| US-9561212-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-02-07 | — | — | US | disclosed |
| US-9561212-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-02-07 | — | — | US | disclosed |
| US-9546160-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-01-17 | — | — | US | disclosed |
| US-9546160-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-01-17 | — | — | US | disclosed |
| US-20160338999-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2016-11-24 | — | — | US | disclosed |
| US-20160338999-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2016-11-24 | — | — | US | disclosed |
| US-9340520-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-05-17 | — | — | US | disclosed |
| US-9340520-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-05-17 | — | — | US | disclosed |
| US-20150252028-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2015-09-10 | — | — | US | disclosed |
| US-20140012020-A1 | Hepatitis C Virus Inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2014-01-09 | — | — | US | disclosed |
| US-20140012020-A1 | Hepatitis C Virus Inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2014-01-09 | — | — | US | disclosed |
| US-8552047-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-10-08 | — | — | US | disclosed |
| US-8552047-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-10-08 | — | — | US | disclosed |
| US-20130121957-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2013-05-16 | — | — | US | disclosed |
| US-20130121957-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2013-05-16 | — | — | US | disclosed |
| US-20130028859-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2013-01-31 | — | — | US | disclosed |
| US-20130028859-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2013-01-31 | — | — | US | disclosed |
| WO-2012154777-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-11-15 | — | — | WO | disclosed |
| WO-2012109080-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-08-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130028859-A1 | Hepatitis C Virus Inhibitors | HAVCR2, PYGL, HCCS | USP30 2534/4885NPC1 65/4885RAB9A 2463/4885 |
| US-20140012020-A1 | Hepatitis C Virus Inhibitors | HAVCR2, PYGL, HCCS | USP30 2534/4885NPC1 65/4885RAB9A 2463/4885 |
| US-20160338999-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, PYGL, HCCS | USP30 2534/4885NPC1 65/4885RAB9A 2463/4885 |
| US-20130121957-A1 | Hepatitis C Virus Inhibitors | HAVCR2, PYGL, HCCS | USP30 2534/4885NPC1 65/4885RAB9A 2463/4885 |
| US-20150252028-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, PYGL, HCCS | USP30 2534/4885NPC1 65/4885RAB9A 2463/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.